Breaking News Instant updates and real-time market news.

BPMC

Blueprint Medicines

$29.37

-0.97 (-3.20%)

18:04
11/30/16
11/30
18:04
11/30/16
18:04

Blueprint Medicines reports 'promising' proof-of-concept data from BLU-285 trial

Blueprint Medicines announced data from its ongoing Phase 1 clinical trial evaluating BLU-285, an investigational medicine for the treatment of patients with advanced gastrointestinal stromal tumors. These data provide proof-of-concept for BLU-285, a potent, highly selective inhibitor of D842V mutant PDGFRalpha and Exon 17 mutant KIT. The data will be presented on Thursday, December 1, 2016 at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany. "The clinical activity observed to date in the dose escalation portion of this Phase 1 study is promising," said Michael Heinrich, M.D., Oregon Health & Science University, an investigator for the clinical trial. "Advanced GIST is a devastating illness, marked by rapid disease progression. Seeing tumor shrinkage in 14 out of 15 PDGFRalpha-driven GIST patients at this point in the study is notable. I am also excited to see tumor shrinkage in four out of the six KIT-driven GIST patients treated at the higher dose levels, indicating the potential for increased clinical activity as we continue to dose-escalate. Given these encouraging early data for this investigational medicine, I believe BLU-285 could be transformative for patients with advanced GIST." BLU-285 is currently being evaluated in the dose escalation stage of a Phase 1 clinical trial in patients with unresectable PDGFRalpha-driven GIST and patients with treatment-resistant KIT-driven GIST. As of the data cutoff date of November 1, 2016, 36 patients had been treated in the dose escalation portion of the Phase 1 clinical trial at seven dose levels, including 18 patients with PDGFRalpha-driven GIST and 18 patients with KIT-driven GIST. The median age was 61, and the median number of prior tyrosine-kinase inhibitor regimens was 3.5. As of the data cutoff date of November 1, 2016, BLU-285 was observed to be well-tolerated at all doses. The majority of adverse events (AEs) reported by investigators were Grade 1 or 2. Across all grades, AEs reported by investigators most commonly included nausea, vomiting, peripheral edema, fatigue and constipation. Investigators reported treatment-related Grade 3 AEs in three patients: nausea and vomiting; anemia and intratumoral hemorrhage; and hypophosphatemia. No dose-limiting toxicities or drug-related Grade 4 or 5 AEs were reported, and no patients discontinued BLU-285 due to treatment-related adverse events. A maximum tolerated dose has not been reached, and enrollment in the dose escalation portion of the Phase 1 clinical trial is ongoing. Based on the favorable safety profile and encouraging clinical activity observed to date in the Phase 1 clinical trial for BLU-285 for the treatment of advanced GIST, Blueprint Medicines will continue to enroll patients in the dose escalation portion of this clinical trial until a MTD or a lower recommended dose for further clinical evaluation has been established. Enrollment in the expansion cohorts for this Phase 1 clinical trial is expected to begin in the first half of 2017. Blueprint Medicines plans to enroll approximately 35 patients with advanced GIST in the expansion cohorts. We also plan to accelerate our evaluation of expanded development options for BLU-285 in GIST, including opportunities to move to earlier lines of therapy and possible combinations.

  • 01

    Dec

  • 03

    Dec

  • 05

    Dec

BPMC Blueprint Medicines
$29.37

-0.97 (-3.20%)

05/27/16
RAJA
05/27/16
INITIATION
Target $23
RAJA
Outperform
Blueprint Medicines initiated with an Outperform at Raymond James
Raymond James analyst Chris Raymond initiated Blueprint Medicines with an Outperform rating and $23 price target. The analyst thinks Blueprint's unique kinase inhibitor discovery platform is well-positioned to generate novel compounds for years to come. Coupling this with a clinical stage pipeline that remains wholly-owned, key proof-of-concept data for two products,BLU-285 and BLU-554, in three different indications by year end 2015, and a valuation offering favorable risk/reward.
08/05/16
ADAM
08/05/16
INITIATION
Target $26
ADAM
Buy
Blueprint Medicines initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated Blueprint Medicines with a Buy and $26 price target.
11/11/16
ADAM
11/11/16
NO CHANGE
Target $35
ADAM
Buy
Blueprint Medicines price target raised to $35 from $26 at Canaccord
Canaccord analyst Arlinda Lee raised her target on Blueprint Medicines to $35 from $26 following company updates on its pipeline of novel, rationally designed, target kinase inhibitors. The analyst increased her probability of success for the company's three programs to 25% from 20% and maintained her Buy rating on Blueprint Medicines shares.
11/29/16
WEDB
11/29/16
NO CHANGE
WEDB
Blueprint Medicines data 'highly encouraging,' says Wedbush
Wedbush analyst David Nierengarten says that Phase I data on Blueprint's BLU-554 for advanced HCC was "highly encouraging." The analyst says that the drug performed well compared with approved HCC therapies. Specifically, he believes that the 10% overall response rate and the fact that four out of ten patients showed radiographic tumor reductions are "promising" signs. The analyst reiterates a $41 price target and an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

ZLAB

Zai Lab

10:51
09/20/17
09/20
10:51
09/20/17
10:51
Syndicate
Breaking Syndicate news story on Zai Lab »

Zai Lab indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

STX

Seagate

$32.18

-1.34 (-4.00%)

10:50
09/20/17
09/20
10:50
09/20/17
10:50
Options
Short-term calls on Seagate see interest for a second time this week »

Short-term calls on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TFX

Teleflex

$237.42

-2.3252 (-0.97%)

10:47
09/20/17
09/20
10:47
09/20/17
10:47
Conference/Events
Teleflex management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 01

    Dec

OFIX

Orthofix

$48.51

-0.49 (-1.00%)

10:45
09/20/17
09/20
10:45
09/20/17
10:45
Conference/Events
Orthofix management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

PFE

Pfizer

$35.93

0.475 (1.34%)

10:45
09/20/17
09/20
10:45
09/20/17
10:45
Options
Pfizer call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 18

    Oct

  • 31

    Oct

10:45
09/20/17
09/20
10:45
09/20/17
10:45
General news
Euro$ interest rate futures are relatively buoyant »

Euro$ interest rate…

ZLAB

Zai Lab

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Syndicate
Breaking Syndicate news story on Zai Lab »

Zai Lab indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

NKTR

Nektar

$21.75

-0.85 (-3.76%)

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Conference/Events
Nektar management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 25

    Sep

MAT

Mattel

$15.05

0.18 (1.21%)

, HAS

Hasbro

$94.99

1.75 (1.88%)

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Hot Stocks
Toymakers in focus after Toys"R"Us files for bankruptcy, Amazon could benefit »

Shares of toymakers,…

MAT

Mattel

$15.05

0.18 (1.21%)

HAS

Hasbro

$94.99

1.75 (1.88%)

JAKK

JAKKS Pacific

$2.83

-0.025 (-0.88%)

KKR

KKR

$19.24

0.15 (0.79%)

VNO

Vornado

$73.34

-0.03 (-0.04%)

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

WMT

Wal-Mart

$80.29

0.24 (0.30%)

JPM

JPMorgan

$94.12

0.18 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 10

    Oct

  • 12

    Oct

  • 22

    Oct

  • 23

    Oct

  • 16

    Nov

  • 21

    Nov

  • 20

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

MODN

Model N

$13.35

-0.15 (-1.11%)

10:43
09/20/17
09/20
10:43
09/20/17
10:43
Conference/Events
Model N management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 16

    Nov

MMM

3M

$210.50

-3.06 (-1.43%)

10:43
09/20/17
09/20
10:43
09/20/17
10:43
Hot Stocks
Analyst says sell 3M amid slowdown in autos, electronics »

JPMorgan downgraded 3M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

ODP

Office Depot

$4.35

-0.07 (-1.58%)

, ADP

ADP

$107.48

0.93 (0.87%)

10:42
09/20/17
09/20
10:42
09/20/17
10:42
Hot Stocks
Office Depot says David Bleisch joins as Chief Legal Officer »

Office Depot (ODP)…

ODP

Office Depot

$4.35

-0.07 (-1.58%)

ADP

ADP

$107.48

0.93 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

10:40
09/20/17
09/20
10:40
09/20/17
10:40
Syndicate
Zai Lab indicated to open at $23, IPO priced at $18 »

Zai Lab (ZLAB) priced 8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

10:40
09/20/17
09/20
10:40
09/20/17
10:40
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

APC

Anadarko

$44.64

0.88 (2.01%)

10:35
09/20/17
09/20
10:35
09/20/17
10:35
Options
Anadarko put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

JCOM

j2 Global

$73.37

-1.52 (-2.03%)

10:35
09/20/17
09/20
10:35
09/20/17
10:35
Conference/Events
j2 Global management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 28

    Sep

PFE

Pfizer

$35.85

0.4 (1.13%)

, JNJ

Johnson & Johnson

$133.60

-1.62 (-1.20%)

10:34
09/20/17
09/20
10:34
09/20/17
10:34
Hot Stocks
Pfizer takes J&J to court as analysts shake up pharma ratings »

Morgan Stanley analyst…

PFE

Pfizer

$35.85

0.4 (1.13%)

JNJ

Johnson & Johnson

$133.60

-1.62 (-1.20%)

LLY

Eli Lilly

$82.24

0.505 (0.62%)

NVS

Novartis

$86.11

0.26 (0.30%)

ABBV

AbbVie

$86.90

0.53 (0.61%)

BMY

Bristol-Myers

$63.08

0.1532 (0.24%)

AGN

Allergan

$211.28

-3.725 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 17

    Oct

  • 18

    Oct

  • 26

    Oct

  • 31

    Oct

  • 09

    Nov

  • 05

    Mar

  • 17

    May

10:31
09/20/17
09/20
10:31
09/20/17
10:31
General news
Crude inventories for week of September 15 »

Crude oil inventories…

PYPL

PayPal

$63.83

0.91 (1.45%)

10:30
09/20/17
09/20
10:30
09/20/17
10:30
Recommendations
PayPal analyst commentary  »

PayPal price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 22

    Oct

  • 29

    Nov

10:30
09/20/17
09/20
10:30
09/20/17
10:30
General news
The 1.7% U.S. August existing home sales drop »

The 1.7% U.S. August…

AAXN

Axon

$22.07

-0.33 (-1.47%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Periodicals
Studies about Taser's safety were overstated, Reuters reports »

Claims about early…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$317.93

-0.25 (-0.08%)

, CBAY

CymaBay

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

BIIB

Biogen

$317.93

-0.25 (-0.08%)

CBAY

CymaBay

EVH

Evolent Health

$16.18

0.5299 (3.39%)

EPZM

Epizyme

$19.25

1.4 (7.84%)

INTU

Intuit

$145.34

1.54 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 03

    Oct

  • 22

    Oct

  • 25

    Oct

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

, UAL

United Continental

$58.01

0.47 (0.82%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

UAL

United Continental

$58.01

0.47 (0.82%)

IR

Ingersoll-Rand

$88.85

-1.61 (-1.78%)

LB

L Brands

$37.40

-1.83 (-4.66%)

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 27

    Sep

  • 02

    Oct

  • 17

    Oct

PFE

Pfizer

$35.91

0.455 (1.28%)

, PGR

Progressive

$47.57

-0.065 (-0.14%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

PFE

Pfizer

$35.91

0.455 (1.28%)

PGR

Progressive

$47.57

-0.065 (-0.14%)

AAL

American Airlines

$44.38

-0.93 (-2.05%)

LUV

Southwest

$53.77

0.23 (0.43%)

POST

Post Holdings

$86.68

0.32 (0.37%)

NDSN

Nordson

$114.62

0.12 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 02

    Oct

  • 18

    Oct

  • 31

    Oct

CELC

Celcuity

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Syndicate
Celcuity opens at $12.35, IPO priced at $9.50 per share »

Celcuity (CELC) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.